Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

U.S. Senate climate, drug bill estimated to cut 10-year deficit by $101.5 billion

Published 08/03/2022, 02:57 PM
Updated 08/03/2022, 06:01 PM
© Reuters. A general view of the sky above the United States Capitol dome in Washington, U.S., June 21, 2022. REUTERS/Mary F. Calvert

By David Morgan and David Lawder

WASHINGTON (Reuters) - A $430 billion drug pricing, energy and tax bill that Democrats hope to fast-track through the U.S. Senate would decrease the federal deficit by a net $101.5 billion over the next decade, the nonpartisan Congressional Budget Office said on Wednesday.

The official CBO forecast is only about one-third of the $300 billion in deficit reduction predicted by Senate Democrats. The CBO estimate did not include a $204 billion tax revenue gain expected from increased Internal Revenue Service enforcement, due to congressional guidelines.

The bill known as the Inflation Reduction Act, introduced last week by Senate Majority Leader Chuck Schumer and Democratic Senator Joe Manchin, represents a key priority for Democrats and President Joe Biden ahead of November's election battle for control of the U.S. Congress.

With the 100-seat Senate split 50-50, Democrats plan to pass the bill without Republican support through a parliamentary process known as reconciliation.

But they cannot afford to lose support from a single lawmaker and one Democrat, Senator Kyrsten Sinema, has not voiced her position on the bill.

Lawmakers are also waiting to hear whether a legislative referee known as the Senate parliamentarian will accept the entire bill as part of the reconciliation process.

With Democrats facing headwinds over inflation and Biden's low job approval numbers, Senate Democrats insist that the bill's deficit reduction effect will help ease inflationary pressures while reducing carbon emissions, lowering prescription drug prices and hiking taxes on wealthy corporations.

"America is on our side. They want us to pass this bill," Schumer said on the Senate floor ahead of the CBO report, citing polling data showing strong public support for the bill and backing from a bipartisan group of former U.S. Treasury secretaries.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The former Treasury secretaries said the bill was "financed by prudent tax policy that will collect more from top earners and large corporations," echoing comments from current Treasury Secretary Janet Yellen

Republicans have rejected Democratic claims that the bill would reduce inflation.

"The only things their 'Inflation Reduction Plan' will reduce is American jobs, wages, after-tax incomes, energy affordability and new life-saving medicines," Senate Republican leader Mitch McConnell said this week.

The CBO said the bill would cut the deficit by $17.9 billion in fiscal 2023, but would increase deficits somewhat from fiscal 2024 though 2027, while cutting deficits again from 2028, with a $42.6 billion deficit reduction in 2031.

Latest comments

The status quo on corporate taxes is just perfect so companies like big oil can keep screwing consumers as they pay no taxes and make their CEO's billionaires. Keep the wealth divide growing as we grow the ranks of serfs and poor.  Tax giveaway of.2017 expedited our downfall
It will cut the deficit on the back off the poor. look at the bill. it's a tax on the poor.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.